CLINICAL TRIALS PROFILE FOR CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58

All Clinical Trials for cyanocobalamin; cyanocobalamin co-57; cyanocobalamin co-58

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004495 ↗	Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis	Completed	Georgetown University	N/A	1999-06-01	OBJECTIVES: I. Compare the efficacy of two doses of folic acid in normalizing plasma total homocysteine concentration in patients with end stage renal disease receiving regular hemodialysis therapy resulting in hyperhomocysteinemia. II. Determine the requirement of co-supplementation with extra pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) daily in these patients. III. Assess the safety and tolerability of this therapy in these patients.
NCT00004734 ↗	Vitamin Therapy for Prevention of Stroke	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 3	1996-09-01	A stroke occurs when part of the brain is damaged from lack of normal blood supply. This may result in difficulty with feeling, speech, muscle strength or coordination, movement, thinking, or other brain functions. Having a stroke increases the risk of another stroke occurring in the future. Higher blood levels of a natural chemical known as homocysteine may contribute to hardening of the arteries in the brain or heart and increase the risk of stroke or heart attack. Folic acid, vitamin B6 (pyridoxine), and vitamin B12 (cyanocobalamin) may lower blood levels of homocysteine and reduce the risk of having another stroke or a heart attack.
NCT00032435 ↗	Homocysteine Study (HOST)	Completed	Abbott Diagnostics Division	Phase 3	2001-05-01	The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
NCT00032435 ↗	Homocysteine Study (HOST)	Completed	Pan American Laboratories	Phase 3	2001-05-01	The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
NCT00032435 ↗	Homocysteine Study (HOST)	Completed	US Department of Veterans Affairs	Phase 3	2001-05-01	The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.

Clinical Trial Conditions for cyanocobalamin; cyanocobalamin co-57; cyanocobalamin co-58

Condition Name

Condition Name for cyanocobalamin; cyanocobalamin co-57; cyanocobalamin co-58
Intervention	Trials
Anaemia	2
End Stage Renal Disease	2
Vitamin B12 Deficiency	2
Healthy	1

Condition MeSH

Condition MeSH for cyanocobalamin; cyanocobalamin co-57; cyanocobalamin co-58
Intervention	Trials
Vitamin B 12 Deficiency	3
Kidney Failure, Chronic	2
Kidney Diseases	2
Urinary Bladder Neoplasms	1

Clinical Trial Locations for cyanocobalamin; cyanocobalamin co-57; cyanocobalamin co-58

Trials by Country

Trials by Country for cyanocobalamin; cyanocobalamin co-57; cyanocobalamin co-58
Location	Trials
United States	140
India	2
Denmark	1
China	1
Puerto Rico	1

Trials by US State

Trials by US State for cyanocobalamin; cyanocobalamin co-57; cyanocobalamin co-58
Location	Trials
Ohio	9
Pennsylvania	8
Illinois	8
Texas	7
Missouri	6

Clinical Trial Progress for cyanocobalamin; cyanocobalamin co-57; cyanocobalamin co-58

Clinical Trial Phase

Clinical Trial Phase for cyanocobalamin; cyanocobalamin co-57; cyanocobalamin co-58
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	5
Phase 2	13

Clinical Trial Status

Clinical Trial Status for cyanocobalamin; cyanocobalamin co-57; cyanocobalamin co-58
Clinical Trial Phase	Trials
Completed	20
Terminated	2
Not yet recruiting	2

Clinical Trial Sponsors for cyanocobalamin; cyanocobalamin co-57; cyanocobalamin co-58

Sponsor Name

Sponsor Name for cyanocobalamin; cyanocobalamin co-57; cyanocobalamin co-58
Sponsor	Trials
National Cancer Institute (NCI)	8
Gynecologic Oncology Group	4
Eastern Cooperative Oncology Group	2

Sponsor Type

Sponsor Type for cyanocobalamin; cyanocobalamin co-57; cyanocobalamin co-58
Sponsor	Trials
Other	25
NIH	9
Industry	6